Scientists have discovered a critical part of the body’s immune system with potentially major implications for the treatment of some of the most devastating diseases affecting humans.
Professor Graham Lord, from The University of Manchester, led the study, which could translate into treatments for autoimmune diseases including Cancer, Diabetes, Multiple Sclerosis and Crohn’s Disease within a few years.
It is published in The Journal of Clinical Investigation today.
The discovery of the molecular pathway regulated by a tiny molecule – known as microRNA-142 – is a major advance in our understanding of the immune system.
The 10-year-study found that microRNA-142 controls Regulatory T cells, which modulate the immune system and prevent autoimmune disease. It is, they found, the most highly expressed regulator in the immune system.
Autoimmune diseases often target people in the prime of their life creating a significant socio-economic burden on them. Sometimes, the effect can be devastating, causing terrible hardship and suffering. But these findings represent a significant step forward in the understanding of the immune system and we believe many people worldwide may benefit
Professor Graham Lord
And according to Professor Lord, the discovery could be translated into a viable drug treatment within a few years.
He said: “Autoimmune diseases often target people in the prime of their life creating a significant socio-economic burden on them. Sometimes, the effect can be devastating, causing terrible hardship and suffering.
“But these findings represent a significant step forward in the understanding of the immune system and we believe many people worldwide may benefit.”
If the activity of Regulatory T cells is too low, this can cause other immune cells to attack our own body tissues. If these Regulatory T cells are too active, this leads to suppression of immune responses and can allow cancers to evade the immune system.
So being able to control them is a major step forward in our ability to control- and harness – the therapeutic power of the immune system.
Professor Richard Jenner from UCL, who led the computational side of the project, said that: “We were able to trace the molecular fingerprints of this molecule across other genes to determine how it acted as such a critical regulator.”
Professor Lord, now Vice President and Dean of the Faculty of Biology, Medicine and Health at The University of Manchester, added: “Scientists over the past decade or so have developed therapies which are able to modulate different pathways of the immune system. We hope that this new discovery will lead to the development of new ways to treat autoimmunity, infectious diseases and cancer and we are incredibly excited about where this may lead.”
The Latest on: Autoimmune diseases
via Google News
The Latest on: Autoimmune diseases
- Despite rising prevalence of heart disease in China, primary preventive treatment rates remain low on February 18, 2019 at 2:10 pm
Beyond its toxic effect, statin use has been associated with a rare, but potentially severe and disabling, type of muscle disease known as statin-associated autoimmune myopathy. Its distinguishing fea... […]
- Global Autoimmune Treatment Market Competitive Strategies, Regional Analysis Forecast 2028 on February 18, 2019 at 2:05 am
Feb 18, 2019 (WiredRelease via COMTEX) -- Autoimmune treatments are done for diseases such as rheumatoid arthritis, lupus, and others, which harm one's healthy body tissue by its own immune system or ... […]
- Innovent Announces a Collaboration with Chipscreen Biosciences to Evaluate the Combination Therapy in Colorectal Cancer Patients on February 17, 2019 at 4:48 pm
Leveraging the platform, the company has built up a robust pipeline of 20 innovative assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular diseases. Fourteen have entered int... […]
- Diabetes, heart disease share risk factors best managed early on February 17, 2019 at 5:30 am
"This is because most people with type 1 diabetes start with the disease much younger in life," said Thomas, adding that type 1 is an autoimmune disease that attacks the cells of the pancreas that mak... […]
- Common gut virus linked to coeliac disease on February 17, 2019 at 5:19 am
Katie Allen from the Murdoch Children’s Research Institute in Melbourne, Australia, who was not involved in the study, says coeliac disease is one of the most common autoimmune conditions in ... […]
- 'Immunology boot camp' emphasizes role of chronic stress in autoimmune disease on February 15, 2019 at 1:25 pm
SCOTTSDALE, Ariz. — Among the most important research in rheumatology over the past two decades has been the role of stress in the onset and course of autoimmune disorders such as rheumatoid arthritis ... […]
- Wendy Williams' Battle With Graves' Disease on February 14, 2019 at 7:41 am
What is Graves' disease? Graves' disease is an autoimmune disorder that causes hyperthyroidism and is the most common cause of hyperthyroidism in the U.S. The disease affects about 1 in 200 people. Gr... […]
- How Viagra puts a brake on a master growth regulator to treat heart disease on February 12, 2019 at 10:02 am
(2019, February 12). How Viagra puts a brake on a master growth regulator to treat heart disease: New findings have implications for heart failure, but also for cancer, diabetes and autoimmune disorde... […]
- IFM Therapeutics launches cGAS/STING-focused subsidiary for inflammatory and autoimmune disease on February 11, 2019 at 5:30 am
IFM Therapeutics is unveiling its second subsidiary: IFM Due, which will target the cyclic GMP-AMP Synthase, Stimulator of Interferon Genes (cGAS/STING) pathway to treat inflammatory and autoimmune di... […]
- IFM Therapeutics, LLC Launches New Subsidiary, IFM Due, to Advance cGAS/STING Antagonists for Serious Inflammatory and Autoimmune Diseases on February 11, 2019 at 4:30 am
BOSTON, Feb. 11, 2019 /PRNewswire/ -- IFM Therapeutics, LLC (IFM), a privately held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, t... […]
via Bing News